S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
Log in

LON:DEST - Destiny Pharma Share Price, Forecast & News

GBX 32
0.00 (0.00 %)
(As of 04/1/2020 04:00 PM ET)
Today's Range
32
Now: GBX 32
33
50-Day Range
32
MA: GBX 35.50
37.50
52-Week Range
32
Now: GBX 32
85
Volume643 shs
Average Volume4,205 shs
Market Capitalization£14.04 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections. The company has collaboration agreement with China Medical System Holdings Limited; and research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis. The company was incorporated in 1996 and is headquartered in Brighton, the United Kingdom.
Read More
Destiny Pharma logo

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1273-704440

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 20.48 per share
Book ValueGBX 23.50 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£14.04 million
Next Earnings DateN/A
OptionableOptionable

Receive DEST News and Ratings via Email

Sign-up to receive the latest news and ratings for DEST and its competitors with MarketBeat's FREE daily newsletter.


Destiny Pharma (LON:DEST) Frequently Asked Questions

How has Destiny Pharma's stock been impacted by COVID-19 (Coronavirus)?

Destiny Pharma's stock was trading at GBX 35.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DEST stock has decreased by 9.9% and is now trading at GBX 32. View which stocks have been mosted impacted by Coronavirus.

How were Destiny Pharma's earnings last quarter?

Destiny Pharma PLC (LON:DEST) announced its quarterly earnings results on Tuesday, April, 9th. The company reported ($11.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($16.20) by $4.30. View Destiny Pharma's earnings history.

Has Destiny Pharma been receiving favorable news coverage?

Media stories about DEST stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Destiny Pharma earned a daily sentiment score of 0.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutDestiny Pharma.

Who are some of Destiny Pharma's key competitors?

What other stocks do shareholders of Destiny Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include African Potash (AFPO), FDM Group (FDM), LiDCO Group (LID), NCC Group (NCC), Photo-Me International (PHTM), Royal Dutch Shell (RDSB), Satellite Solutions Worldwide (SAT), Shanta Gold (SHG), Somero Enterprises (SOM) and Greencoat UK Wind (UKW).

Who are Destiny Pharma's key executives?

Destiny Pharma's management team includes the following people:
  • Mr. Neil Robert Clark, CEO & Director (Age 56)
  • Dr. William Guy Love, Founder, Chief Scientific Officer & Director (Age 56)
  • Mr. Shaun Claydon, CFO, Company Sec. & Director (Age 51)
  • Dr. Jesús M González Moreno, Chief Medical Officer

What is Destiny Pharma's stock symbol?

Destiny Pharma trades on the London Stock Exchange (LON) under the ticker symbol "DEST."

How do I buy shares of Destiny Pharma?

Shares of DEST and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Destiny Pharma's stock price today?

One share of DEST stock can currently be purchased for approximately GBX 32.

How big of a company is Destiny Pharma?

Destiny Pharma has a market capitalization of £14.04 million.  View additional information about Destiny Pharma.

What is Destiny Pharma's official website?

The official website for Destiny Pharma is http://www.destinypharma.com/.

How can I contact Destiny Pharma?

Destiny Pharma's mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The company can be reached via phone at +44-1273-704440.


MarketBeat Community Rating for Destiny Pharma (LON DEST)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about Destiny Pharma and other stocks. Vote "Outperform" if you believe DEST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel